Deliang Guo PhD

Asst ProfessorCollege of Medicinedeliang.guo@osumc.edu

Wiseman Hall 400 W 12th Avenue Columbus OH 43210

Phone:614-366-3774Fax: 614-247-1877

Experimental Therapeutics

General Research Interest

Oncogenic signaling transduction and cancer metabolism.

Research Description

Dr. Guo’s lab is focusing on EGFR/RTKs/PI3K/Akt and Ras/MEK/ERK signaling transduction and cancer metabolism. Recently he uncovered EGFR/PI3K/Akt signaling upregulates SREBP-1 activity to promote de novo fatty acid synthesis and increase cholesterol uptake in brain tumor patients, and demonstrate SREBP-1 and its regulated key genes ACC, FAS and LDLR as novel molecular targets in cancer. Dr. Guo's work is committed to unraveling how EGFR/PI3K signaling regulates metabolism network, to unravel the link between glucose uptake and lipid metabolism, to identify the key molecular targets in this network and develop potent inhibitors to translate into clinical trial to eradicate cancer cells.

Current Publications

Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, Dejesus J, Lisiero DD, Huang TT, Prins RM, Wen PY, Robins HI, Prados MD, Deangelis LM, Mellinghoff IK, Mehta MP, James CD, Chakravarti A, Cloughesy TF, Tontonoz P, Mischel PSAn LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.Cancer Discov 1(5) 442-56 10/1/2011